Tramadol News and Research

RSS

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy.

18 May 2012

Ampio submits pre-IND package on Zertane to FDA

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, announced today that it submitted to the FDA a pre IND package on Zertane, its on-demand premature ejaculation drug, for a meeting and discussion on the approval path under the 505(b) 2 regulation/registration requirement in the US.

9 Apr 2012

ASN participates in ABIM Foundation's Choosing Wisely campaign

The American Society of Nephrology (ASN), the world's leading kidney organization, joins the American Board of Internal Medicine (ABIM) Foundation, eight other leading national medical specialty societies, and Consumer Reports in the new Choosing Wisely campaign that helps health care professionals and patients avoid wasteful and sometimes harmful medical interventions.

5 Apr 2012

Ampio, Australian TGA reach agreement over Zertane submission plan

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, announced today that it reached agreement with the Therapeutic Goods Administration, Canberra, Australia, on a plan of drug manufacture and quality control for Zertane and the overall plan for the preparation of Common Technical Documents for the draft registration submission expected to be filed in June 2012.

2 Apr 2012

New ACR guidelines recommend use of topical NSAIDs for older patients with knee OA

The American College of Rheumatology (ACR) Subcommittee on Osteoarthritis Guidelines has approved and issued several updates to clinical practice guidelines for the treatment of osteoarthritis (OA).

31 Mar 2012

New NPS information on dextropropoxyphene: recommendations and alternatives

NPS has published information online for prescribers to help them prepare for the TGA’s cancellation of Capadex and Paradex, two of the four medicines available in Australia containing dextropropoxyphene.

1 Mar 2012

Ampio announces two new European patents for Zertane combination therapy

Ampio Pharmaceuticals, Inc., today announced notification by the European Patent Office they will be awarded two new patents in Europe for the combination of Zertane with any erectile dysfunction drug of the PDE5 inhibitors family such as sildenafil, tadalafil and the likes and for a combination of Zertane with compounds that reduce the side effects of tramadol.

18 Jan 2012

Medical websites provide harmful information about postherpetic neuralgia treatments

Health information is plentiful on the Internet and many Web surfers consider medical advice they find online to be a cheaper alternative to visiting a doctor, according to some studies. However, the risk of obtaining useless or even harmful medical information from some websites is high for patients with postherpetic neuralgia, a common complication of shingles, according to new research reported in The Journal of Pain, published by the American Pain Society.

1 Dec 2011

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.

31 Oct 2011

Cipher net revenue decreases to $0.7 million for Q2 2011

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three and six months ended June 30, 2011.

26 Jul 2011

Cipher grants Vertical exclusive U.S. distribution rights to CIP-TRAMADOL ER

Cipher Pharmaceuticals Inc. today announced that it has entered into a definitive distribution and supply agreement with Vertical Pharmaceuticals, Inc., a U.S.-based specialty pharmaceutical company, under which Cipher has granted Vertical the exclusive right to market, sell and distribute CIP-TRAMADOL ER in the United States.

29 Jun 2011

Top-line results from Cipher's CIP-ISOTRETINOIN Phase III study against severe nodular acne

Cipher Pharmaceuticals Inc. today provided top-line safety and efficacy results from the Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin for the treatment of severe, nodular acne.

8 Jun 2011

Cipher first quarter net revenue decreases to $0.7 million

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three months ended March 31, 2011.

12 May 2011

Labopharm first quarter total revenue increases to $5.3 million

Labopharm Inc. today reported its progress and financial results for the first quarter ended March 31, 2011.

4 May 2011

Health Canada approves Labopharm's OLEPTRO for treatment of Major Depressive Disorder

Labopharm Inc. today announced that Health Canada's Therapeutic Products Directorate (TPD) has approved OLEPTRO, a novel once-daily formulation of the antidepressant trazodone, for the symptomatic relief of Major Depressive Disorder in adults.

21 Jan 2011

Labopharm monetizes future royalty payment stream for RYZOLT through subsidiary

Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).

3 Jan 2011

Cipher Phase 3 dermatology study uses MedAvante Centralized Ratings

MedAvante, Inc., the leader in centralized expert evaluation of treatments for central nervous system disorders, announced that Cipher Pharmaceuticals is using MedAvante Centralized Ratings in their pivotal Phase 3 dermatology study.

8 Dec 2010

Labopharm receives notice about Activis' ANDA for OLEPTRO

Labopharm Inc. today announced that on November 11, 2010 it received notice from Actavis South Atlantic LLC advising that Actavis has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval to market 150 and 300 mg generic versions of OLEPTRO (trazodone hydrochloride extended-release 150 and 300 mg tablets) in the United States.

15 Nov 2010

Labopharm receives notice of Activis' ANDA submission for generic OLEPTRO

Labopharm Inc. today announced that on November 11, 2010 it received notice from Actavis South Atlantic LLC advising that Actavis has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval to market 150 and 300 mg generic versions of OLEPTRO™ (trazodone hydrochloride extended-release 150 and 300 mg tablets) in the United States.

12 Nov 2010